FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2019
Price : $35 *
At a glance
- Drugs CDX 301 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 May 2018 Results presented in the Celldex Therapeutics Inc media release.
- 20 Apr 2018 Results (n=9) presented in a Celldex Therapeutics Inc media release.
- 20 Apr 2018 According to a Celldex Therapeutics Inc media release, the data (n=9) from this study has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.